Brief: Epigenomics AG Ends License Agreement With Biochain, Reports 2019 Outlook

Epigenomics AG

06/03/2019 20:05

March 6 (Reuters) - Epigenomics AG  ECXn.DE :
    * TERMINATES COLLABORATION WITH CHINESE LICENSING PARTNER
AND
ANNOUNCES ANTICIPATED REVENUE GROWTH IN 2019 OUTLOOK
    * EXPECTS REVENUES TO BE IN A RANGE OF EUR 3.0 MILLION TO
6.0
MILLION FOR 2019
    * GIVEN TERMINATION OF LICENSE AGREEMENT WITH BIOCHAIN,
FUTURE
LICENSING REVENUE ON CHINESE MARKET IS NOT INCLUDED IN OUTLOOK
FOR 2019
    * FY 2019 ADJUSTED EBITDA (EBITDA BEFORE SHARE-BASED PAYMENT
EXPENSES) IS EXPECTED TO BE IN RANGE OF EUR -11.5 MILLION TO EUR
-14.0 MILLION
    * EPIGENOMICS- DECIDED TO TERMINATE COLLABORATION WITH
BIOCHAIN
FOR LICENSING OF SEPTIN9 MARKER AND EXCLUSIVE DISTRIBUTION
RIGHTS IN CHINA FOR EPI PROCOLON

Source text for Eikon:  ID:nEQ4PLxK8a 
Further company coverage:  ECXn.DE 

 ((Reuters.Briefs@thomsonreuters.com;))